Claims for Patent: 10,232,014

✉ Email this page to a colleague

Summary for Patent: 10,232,014

Title:	Tear lipocalin muteins binding IL-4 R alpha
Abstract:	The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
Inventor(s):	Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
Assignee:	Pieris Pharmaceuticals GmbH
Application Number:	US15/613,958

Details for Patent 10,232,014

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004	⤷ Start Trial	2037-06-05
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009	⤷ Start Trial	2037-06-05
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009	⤷ Start Trial	2037-06-05
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	January 31, 2020	⤷ Start Trial	2037-06-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,232,014

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	201209160	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2011154420	⤷ Start Trial
United States of America	9687524	⤷ Start Trial
United States of America	8986951	⤷ Start Trial
United States of America	2021196788	⤷ Start Trial
United States of America	2019240289	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.